FDA approves Jakafi to treat patients with a chronic type of bone marrow disease

Share this content:
FDA approves Jakafi to treat patients with a chronic type of bone marrow disease
FDA approves Jakafi to treat patients with a chronic type of bone marrow disease
The U.S. Food and Drug Administration have approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Polycythemia vera occurs when too many red blood cells are made in the bone marrow. An overabundance of blood cells can cause the spleen to swell, bleeding problems and blood clots in the veins near the skin surface (phlebitis).
READ FULL ARTICLE From Medical News Today
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »